Validation of Overactive Bladder Questionnaire (1-week Recall Version) in Medically Complex Elderly Patients with Overactive Bladder

Overview

Journal Int Urogynecol J

Publisher Springer

Specialties Gynecology & Obstetrics
Urology

Date 2017 Apr 6

PMID 28378111

Authors

Alexandra I Barsdorf

Martin Carlsson

Andrew G Bushmakin

Sheila Quinn

Joseph C Cappelleri

Andreas Pleil

Affiliations

Soon will be listed here.

Abstract

Introduction: The 33-item Overactive Bladder questionnaire (OAB-q; 1-week recall version) has been psychometrically validated in middle-aged, generally healthy patients with overactive bladder. The present analysis was conducted to determine the psychometric validity of the OAB-q in medically complex elderly patients.

Methods: OAB-q structure was evaluated using a second-order confirmatory factor analysis (CFA) model with five domains and one aggregated domain, using pooled data from two clinical trials (786 observations) for urgency urinary incontinence (UUI). Psychometric validity was evaluated with CFA, Cronbach coefficient α (CCA) for reliability, Spearman correlations for convergent validity, differences in OAB-q scores in relation to UUI severity and Patient Perception of Bladder Condition (PPBC) scores for known-groups validity, and effect size (ES) of differences in mean scores of OAB-q domains over time for treatment responsiveness.

Results: Participants were predominantly female (82.2%) and white (85.9%); mean age was 75.0 years. The second-order CFA was confirmed with a Bentler's comparative fit index of 0.90, t values for path coefficients of >1.96, and standardized path coefficients of >0.40. OAB-q domains demonstrated good internal consistency (CCA >0.7). Convergent validity was supported by moderate correlations (0.4-0.7) between OAB-q domain and PPBC scores. Significant differences in OAB-q domain scores between groups with different symptom severity established known-groups validity. Significant changes in mean OAB-q scores from baseline to week 12 with moderate-to-large ES (0.50-0.80) demonstrated treatment responsiveness.

Conclusions: The OAB-q demonstrates reliability, concurrent and discriminant validity, and responsiveness to treatment. The evidence shows that the OAB-q is psychometrically sound for use in medically complex elderly patients with overactive bladder.

References

Coyne K, Matza L, Thompson C, Kopp Z, Khullar V . Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006; 176(2):627-32. DOI: 10.1016/j.juro.2006.03.088. View

Gibson W, Athanasopoulos A, Goldman H, Madersbacher H, Newman D, Spinks J . Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?. Int J Clin Pract. 2014; 68(9):1165-73. DOI: 10.1111/ijcp.12447. View

Coyne K, Sexton C, Kopp Z, Ebel-Bitoun C, Milsom I, Chapple C . The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011; 108(9):1459-71. DOI: 10.1111/j.1464-410X.2010.10013.x. View

Wagg A, Khullar V, Marschall-Kehrel D, Michel M, Oelke M, Darekar A . Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013; 61(2):185-93. DOI: 10.1111/jgs.12088. View

Irwin D, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S . Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6):1306-14. DOI: 10.1016/j.eururo.2006.09.019. View

Coyne K, Gelhorn H, Thompson C, Kopp Z, Guan Z . The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J. 2011; 22(12):1555-63. DOI: 10.1007/s00192-011-1486-0. View

Chancellor M, de Miguel F . Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics. 2007; 62(5):15-24. View

Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J . Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002; 11(6):563-74. DOI: 10.1023/a:1016370925601. View

Liberman J, Hunt T, Stewart W, Wein A, Zhou Z, Herzog A . Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001; 57(6):1044-50. DOI: 10.1016/s0090-4295(01)00986-4. View

10.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U . The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002; 187(1):116-26. DOI: 10.1067/mob.2002.125704. View

11.

Coyne K, Margolis M, Hsieh R, Vats V, Chapple C . Validation of the urinary sensation scale (USS). Neurourol Urodyn. 2011; 30(3):360-5. DOI: 10.1002/nau.21005. View

12.

Saliba D, Elliott M, Rubenstein L, Solomon D, Young R, Kamberg C . The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2002; 49(12):1691-9. DOI: 10.1046/j.1532-5415.2001.49281.x. View

13.

Coyne K, Sexton C, Vats V, Thompson C, Kopp Z, Milsom I . National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011; 77(5):1081-7. DOI: 10.1016/j.urology.2010.08.039. View

14.

DuBeau C, Kraus S, Griebling T, Newman D, Wyman J, Johnson 2nd T . Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2013; 191(2):395-404. DOI: 10.1016/j.juro.2013.08.027. View

15.

Coyne K, Matza L, Thompson C . The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005; 14(3):849-55. DOI: 10.1007/s11136-004-0706-1. View

16.

Abrams P, Artibani W, Gajewski J, Hussain I . Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology. 2006; 68(2 Suppl):17-28. DOI: 10.1016/j.urology.2006.05.044. View

17.

Irwin D, Milsom I, Kopp Z, Abrams P, Cardozo L . Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2005; 97(1):96-100. DOI: 10.1111/j.1464-410X.2005.05889.x. View

18.

Delafuente J . Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003; 48(2):133-43. DOI: 10.1016/j.critrevonc.2003.04.004. View

19.

Coyne K, Matza L, Kopp Z, Abrams P . The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006; 49(6):1079-86. DOI: 10.1016/j.eururo.2006.01.007. View

20.

Helfand B, Evans R, McVary K . A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol. 2009; 57(4):586-91. DOI: 10.1016/j.eururo.2009.12.025. View